CliffBio
small molecule

TOBRADEX ST

DEXAMETHASONE; TOBRAMYCIN

Loss of exclusivityAugust 2028latest FDA-listed patent expiry
CompanyHARROW EYE LLC

Drug detail

Brand nameTOBRADEX ST
Active ingredientDEXAMETHASONE; TOBRAMYCIN
Strength0.05%;0.3%
Dosage formSUSPENSION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalFebruary 2009
Marketing statusRX

Listed patents

PatentExpiresType
7795316August 2028product
8101582December 2027product
8450287December 2027product

More from HARROW EYE LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TOBRADEX ST patent cliff — loss of exclusivity August 2028 | CliffBio